Lebrikizumab Eased Itch and Pain in Hand and Foot Eczema: ADtouch
New ADtouch findings reported by HCPLive show lebrikizumab eased itch and pain in hand and foot eczema — the sites patients feel most in daily function.
Topic
Topic
New ADtouch findings reported by HCPLive show lebrikizumab eased itch and pain in hand and foot eczema — the sites patients feel most in daily function.
A 48-week real-world retrospective study on Springer Nature Link tracks lebrikizumab in atopic dermatitis patients who switched f…
Lebrikizumab sustained skin clearance and itch reduction in atopic dermatitis across four years of follow-up, per HCPLive's long-…
Two moderate-to-severe atopic dermatitis patients in Mexico improved on lebrikizumab in routine practice, per a Cureus case repor…
Selective IL-13 inhibition with lebrikizumab showed benefit in pediatric atopic dermatitis, per a new medical reference summary f…
Eli Lilly's EBGLYSS label update from the FDA allows one subcutaneous maintenance dose every eight weeks for adults with moderate…
Phase 3 data show lebrikizumab improved atopic dermatitis symptoms and itch in children, extending IL-13 inhibition evidence into…
Eli Lilly's Ebglyss cleared or nearly cleared hand and foot eczema in 53% of patients versus 27% on placebo, per Medical Daily, f…
Lebrikizumab maintains improvements in itch and lesions for up to five years in moderate-to-severe atopic dermatitis, extending t…
Lilly reports Phase 3b data showing EBGLYSS (lebrikizumab-lbkz) achieved significant, rapid improvements in skin clearance, itch,…